Home LiteratureArticle Details
PMID: 12727914 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Antimicrobial resistance: the example of Staphylococcus aureus.

The Journal of clinical investigation ·Vol. 111 ·No. 9 ·2003-05-00 ·Pages 1265-73

Lowy FD

Abstract

暂无摘要

MeSH Terms
Anti-Bacterial Agents/metabolism,pharmacology,therapeutic use Cross Infection Drug Resistance, Bacterial Humans Penicillins/metabolism,pharmacology,therapeutic use Quinolones/metabolism,pharmacology,therapeutic use Staphylococcal Infections/drug therapy,microbiology Staphylococcus aureus/drug effects,genetics,physiology Vancomycin/metabolism,pharmacology,therapeutic use
Chemicals
Anti-Bacterial Agents Penicillins Quinolones Vancomycin
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Lowy Franklin D
Departments of Medicine and Pathology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA. fl189@columbia.edu
References (94)
94 references, click to expand
  1. A Dutch approach to methicillin-resistant Staphylococcus aureus.
    Eur J Clin Microbiol Infect Dis. 1999 Jul;18(7):461-6 PMID: 10482021
  2. Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri.
    Microb Drug Resist. 1996 Winter;2(4):377-91 PMID: 9158808
  3. Development of methicillin resistance in clinical isolates of Staphylococcus sciuri by transcriptional activation of the mecA homologue native to s.
    J Bacteriol. 2003 Jan;185(2):645-53 PMID: 12511511
  4. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk.
    JAMA. 1998 Feb 25;279(8):593-8 PMID: 9486753
  5. Changing staphylococci and staphylococcal infections. A ten-year study of bacteria and cases of bacteremia.
    N Engl J Med. 1969 Sep 18;281(12):627-35 PMID: 5194719
  6. Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus.
    J Biol Chem. 1999 Jul 2;274(27):18942-6 PMID: 10383392
  7. Use of antimicrobial agents and drug resistance.
    N Engl J Med. 1997 Aug 14;337(7):491-2 PMID: 9250853
  8. In vitro bactericidal activity of daptomycin against staphylococci.
    J Antimicrob Chemother. 2002 Mar;49(3):467-70 PMID: 11864946
  9. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community.
    J Clin Microbiol. 2002 Nov;40(11):4289-94 PMID: 12409412
  10. Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staphylococcus aureus N315.
    Antimicrob Agents Chemother. 1999 Jun;43(6):1449-58 PMID: 10348769
  11. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.
    Antimicrob Agents Chemother. 1998 Jun;42(6):1355-60 PMID: 9624475
  12. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991.
    Infect Control Hosp Epidemiol. 1992 Oct;13(10):582-6 PMID: 1469266
  13. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.
    Clin Infect Dis. 2001 May 15;32 Suppl 2:S114-32 PMID: 11320452
  14. The emergence and evolution of methicillin-resistant Staphylococcus aureus.
    Trends Microbiol. 2001 Oct;9(10):486-93 PMID: 11597450
  15. Penicillin resistant staphylococci.
    Proc Soc Exp Biol Med. 1945 Oct;60:55-8 PMID: 21004029
  16. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.
    Clin Microbiol Rev. 1997 Oct;10(4):781-91 PMID: 9336672
  17. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community.
    Curr Opin Infect Dis. 2002 Aug;15(4):407-13 PMID: 12130938
  18. Diminished virulence of a sar-/agr- mutant of Staphylococcus aureus in the rabbit model of endocarditis.
    J Clin Invest. 1994 Nov;94(5):1815-22 PMID: 7962526
  19. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis.
    N Engl J Med. 1986 Jul 10;315(2):91-6 PMID: 3523240
  20. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Antimicrob Agents Chemother. 1996 Aug;40(8):1881-8 PMID: 8843298
  21. Staphylococcus aureus sortase mutants defective in the display of surface proteins and in the pathogenesis of animal infections.
    Proc Natl Acad Sci U S A. 2000 May 9;97(10):5510-5 PMID: 10805806
  22. mecA-blaZ corepressors in clinical Staphylococcus aureus isolates.
    Antimicrob Agents Chemother. 2003 Apr;47(4):1460-3 PMID: 12654694
  23. Vancomycin resistance plasmid in Enterococcus faecalis that encodes sensitivity to a sex pheromone also produced by Staphylococcus aureus.
    Antimicrob Agents Chemother. 2001 Jul;45(7):2177-8 PMID: 11441824
  24. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
    J Antimicrob Chemother. 1997 Jul;40(1):135-6 PMID: 9249217
  25. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50.
    J Antimicrob Chemother. 1998 Sep;42(3):315-20 PMID: 9786471
  26. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.
    Lancet. 1997 Dec 6;350(9092):1670-3 PMID: 9400512
  27. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997-1999.
    MMWR Morb Mortal Wkly Rep. 1999 Aug 20;48(32):707-10 PMID: 21033181
  28. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin.
    Antimicrob Agents Chemother. 2000 Jun;44(6):1428-37 PMID: 10817688
  29. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community.
    JAMA. 2001 Sep 12;286(10):1201-5 PMID: 11559265
  30. Activity of and resistance to moxifloxacin in Staphylococcus aureus.
    Antimicrob Agents Chemother. 2003 Apr;47(4):1410-5 PMID: 12654680
  31. The evolution of methicillin resistance in Staphylococcus aureus: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones.
    Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9865-70 PMID: 11481426
  32. Molecular evolution of MRSA.
    Microbiol Immunol. 1995;39(8):531-43 PMID: 7494490
  33. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.
    Clin Infect Dis. 2003 Feb 15;36(4):429-39 PMID: 12567300
  34. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.
    Annu Rev Microbiol. 2002;56:657-75 PMID: 12142482
  35. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    N Engl J Med. 1999 Feb 18;340(7):493-501 PMID: 10021469
  36. Expression of resistance to methicillin.
    Trends Microbiol. 1994 Oct;2(10):389-93 PMID: 7850207
  37. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia.
    Rev Infect Dis. 1987 Sep-Oct;9(5):891-907 PMID: 3317734
  38. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.
    Clin Microbiol Rev. 1997 Jul;10(3):505-20 PMID: 9227864
  39. Genome and virulence determinants of high virulence community-acquired MRSA.
    Lancet. 2002 May 25;359(9320):1819-27 PMID: 12044378
  40. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus.
    Nat Struct Biol. 2002 Nov;9(11):870-6 PMID: 12389036
  41. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus.
    Antimicrob Agents Chemother. 2000 Jun;44(6):1549-55 PMID: 10817707
  42. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Antimicrob Agents Chemother. 2001 Nov;45(11):3076-83 PMID: 11600359
  43. Antimicrobials: new solutions badly needed.
    Curr Opin Microbiol. 2002 Oct;5(5):463-5 PMID: 12354551
  44. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus.
    Proc Natl Acad Sci U S A. 2002 May 14;99(10):6573-8 PMID: 11997460
  45. Staphylococcal vaccines.
    Trends Immunol. 2002 Sep;23(9):461-3 PMID: 12200069
  46. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 2003 Jan;47(1):196-203 PMID: 12499191
  47. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus.
    Science. 1993 Jan 8;259(5092):227-30 PMID: 8093647
  48. Unusually large number of methicillin-resistant Staphylococcus aureus clones in a Portuguese hospital.
    J Clin Microbiol. 1995 Aug;33(8):2032-5 PMID: 7559943
  49. Fluoroquinolone resistance among Gram-positive cocci.
    Lancet Infect Dis. 2002 Sep;2(9):530-8 PMID: 12206969
  50. Distribution of genes encoding resistance to streptogramin A and related compounds among staphylococci resistant to these antibiotics.
    Antimicrob Agents Chemother. 1996 Nov;40(11):2523-8 PMID: 8913457
  51. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome.
    Antimicrob Agents Chemother. 1994 Jun;38(6):1345-55 PMID: 8092836
  52. Evolutionary genomics of Staphylococcus aureus: insights into the origin of methicillin-resistant strains and the toxic shock syndrome epidemic.
    Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8821-6 PMID: 11447287
  53. Studies of the repressor (BlaI) of beta-lactamase synthesis in Staphylococcus aureus.
    Mol Microbiol. 1997 Jun;24(5):1025-37 PMID: 9220009
  54. A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci.
    Science. 2001 Mar 9;291(5510):1962-5 PMID: 11239156
  55. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci.
    Antimicrob Agents Chemother. 1991 Jan;35(1):124-9 PMID: 2014967
  56. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA).
    Proc Natl Acad Sci U S A. 2002 May 28;99(11):7687-92 PMID: 12032344
  57. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.
    J Antimicrob Chemother. 1998 Aug;42(2):199-209 PMID: 9738837
  58. Emergence of vancomycin resistance in coagulase-negative staphylococci.
    N Engl J Med. 1987 Apr 9;316(15):927-31 PMID: 3821839
  59. Signaling antibiotic resistance in staphylococci.
    Science. 2001 Mar 9;291(5510):1915-6 PMID: 11245199
  60. Molecular epidemiology of multiresistant Staphylococcus aureus in Australian hospitals.
    J Med Microbiol. 1984 Feb;17(1):79-89 PMID: 6319704
  61. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.
    Clin Infect Dis. 2003 Jan 1;36(1):53-9 PMID: 12491202
  62. Historical yearly usage of vancomycin.
    Antimicrob Agents Chemother. 1998 May;42(5):1303-4 PMID: 9593175
  63. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains.
    Antimicrob Agents Chemother. 2002 Apr;46(4):1147-52 PMID: 11897611
  64. Phage antibacterials make a comeback.
    Nat Biotechnol. 2001 Aug;19(8):734-5 PMID: 11479562
  65. Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002.
    MMWR Morb Mortal Wkly Rep. 2002 Oct 11;51(40):902 PMID: 12418544
  66. Epidemiology of drug resistance: implications for a post-antimicrobial era.
    Science. 1992 Aug 21;257(5073):1050-5 PMID: 1509255
  67. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 1985 Sep;28(3):397-403 PMID: 3878127
  68. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus.
    J Bacteriol. 1984 May;158(2):513-6 PMID: 6563036
  69. Staphylococcus aureus resistant to vancomycin--United States, 2002.
    MMWR Morb Mortal Wkly Rep. 2002 Jul 5;51(26):565-7 PMID: 12139181
  70. Exploiting genomics to discover new antibiotics.
    Trends Microbiol. 2001 Dec;9(12):611-7 PMID: 11728875
  71. Molecular structures of penicillin-binding proteins and beta-lactamases.
    Trends Microbiol. 1994 Oct;2(10):372-80 PMID: 7850204
  72. Methicillin resistance in Staphylococcus aureus.
    Lancet. 1970 Apr 18;1(7651):800-4 PMID: 4191434
  73. The changing epidemiology of Staphylococcus aureus?
    Emerg Infect Dis. 2001 Mar-Apr;7(2):178-82 PMID: 11294701
  74. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala.
    Science. 1999 Apr 16;284(5413):507-11 PMID: 10205063
  75. Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop.
    N Engl J Med. 1994 Apr 28;330(17):1247-51 PMID: 8139650
  76. The evolution of pandemic clones of methicillin-resistant Staphylococcus aureus: identification of two ancestral genetic backgrounds and the associated mec elements.
    Microb Drug Resist. 2001 Winter;7(4):349-61 PMID: 11822775
  77. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.
    N Engl J Med. 2002 Feb 14;346(7):491-6 PMID: 11844850
  78. New (and not so new) antibacterial targets - from where and when will the novel drugs come?
    Curr Opin Pharmacol. 2002 Oct;2(5):513-22 PMID: 12324252
  79. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.
    N Engl J Med. 1999 Feb 18;340(7):517-23 PMID: 10021472
  80. Methicillin-resistant Staphylococcus aureus as a community organism.
    Clin Infect Dis. 1995 Nov;21(5):1308-12 PMID: 8589164
  81. Role of mecA transcriptional regulation in the phenotypic expression of methicillin resistance in Staphylococcus aureus.
    J Bacteriol. 1996 Sep;178(18):5464-71 PMID: 8808937
  82. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci.
    Antimicrob Agents Chemother. 1999 May;43(5):1062-6 PMID: 10223914
  83. Linezolid resistance in a clinical isolate of Staphylococcus aureus.
    Lancet. 2001 Jul 21;358(9277):207-8 PMID: 11476839
  84. What determines nasal carriage of Staphylococcus aureus?
    Trends Microbiol. 2001 Dec;9(12):605-10 PMID: 11728874
  85. Vancomycin-resistant enterococcal infections.
    N Engl J Med. 2000 Mar 9;342(10):710-21 PMID: 10706902
  86. EXTRACTION OF A HIGHLY POTENT PENICILLIN INACTIVATOR FROM PENICILLIN RESISTANT STAPHYLOCOCCI.
    Science. 1944 Jun 2;99(2579):452-3 PMID: 17798398
  87. Evolution of an inducible penicillin-target protein in methicillin-resistant Staphylococcus aureus by gene fusion.
    FEBS Lett. 1987 Aug 31;221(1):167-71 PMID: 3305073
  88. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis.
    Lancet. 1997 Jan 18;349(9046):167-9 PMID: 9111541
  89. Antimicrobial resistance of Staphylococcus aureus: genetic basis.
    Microbiol Rev. 1987 Mar;51(1):88-134 PMID: 3031442
  90. VanA-mediated high level glycopeptide resistance in MRSA.
    Lancet Infect Dis. 2003 Feb;3(2):67-8 PMID: 12560187
  91. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections.
    N Engl J Med. 2002 Jun 13;346(24):1871-7 PMID: 12063371
  92. Origin and evolution of DNA associated with resistance to methicillin in staphylococci.
    Trends Microbiol. 1994 Oct;2(10):343-7 PMID: 7850198
  93. Staphylococcus aureus infections.
    N Engl J Med. 1998 Aug 20;339(8):520-32 PMID: 9709046
  94. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001.
    Am J Infect Control. 2001 Dec;29(6):404-21 PMID: 11743489
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
DOI
10.1172/JCI18535
Email
fl189@columbia.edu
Published
2003-05-00
Pages
1265-73
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC154455
Subset
IM
Grants
NIDA NIH HHS · R01 DA011868 · United States
NIDA NIH HHS · R01 DA015018 · United States
External Links
PubMed source DOI: 10.1172/JCI18535 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2